We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXeris Biopharma Regulatory News (0A8E)

Share Price Information for Xeris Biopharma (0A8E)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.708734
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.708734
0A8E Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Xeris Pharmaceuticals, Inc

10 Jun 2021 13:32

RNS Number : 5272B
Lazard Asset Management
10 June 2021
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Lazard Asset Management Ltd.

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

 Xeris Pharmaceuticals, Inc.

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

 09 June 2021

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

No

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ord

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

2,777,775 

4.185%

(2) Cash-settled derivatives:

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

 2,777,775 

4.185%

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Ord

Ord

Ord

 

CFD

CFD

CFD

Buy to Cover

Short Sell

Short Sell

5488

25269

23326

USD 4.0548

USD 4.0458

USD 4.0557

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

 

 

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

10 June 2021

Contact name:

Harrison Leney

Telephone number:

020 7448 2335

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETLBLFFFQLXBBB
Date   Source Headline
7th Oct 20213:09 pmRNSXeris Pharmaceuticals, Inc 8.3
6th Oct 20212:43 pmRNSXeris Pharmaceuticals, Inc 8.3
6th Oct 20212:42 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
5th Oct 20215:06 pmRNSXeris Pharmaceuticals, Inc 8.3 Amend
5th Oct 20213:15 pmRNSXeris Pharmaceuticals, Inc 8.3
4th Oct 20211:04 pmRNSXeris Pharmaceuticals, Inc 8.3
1st Oct 20213:05 pmRNSXeris Pharmaceuticals, Inc 8.3
1st Oct 202110:14 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
30th Sep 20215:07 pmRNSXeris Pharmaceuticals, Inc 8.3
30th Sep 20212:58 pmRNSXeris Pharmaceuticals, Inc 8.3
30th Sep 202110:22 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
29th Sep 20212:36 pmRNSXeris Pharmaceuticals, Inc 8.3
28th Sep 20212:22 pmRNSXeris Pharmaceuticals, Inc 8.3
28th Sep 20212:21 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
28th Sep 20212:19 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
27th Sep 202112:27 pmRNSXeris Pharmaceuticals, Inc 8.3
24th Sep 20214:35 pmRNSXeris Pharmaceuticals, Inc 8.3
24th Sep 20211:05 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
23rd Sep 20212:35 pmRNSXeris Pharmaceuticals, Inc 8.3
23rd Sep 20212:18 pmEQSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc
22nd Sep 20213:00 pmRNSXeris Pharmaceuticals, Inc 8.3
22nd Sep 20212:12 pmEQSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc
22nd Sep 202112:18 pmRNSForm 8.3 - XERIS PHARMACEUTICALS INC
21st Sep 20213:03 pmRNSXeris Pharmaceuticals, Inc 8.3
21st Sep 20212:17 pmEQSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc
21st Sep 20211:40 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
20th Sep 20211:53 pmEQSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc
20th Sep 202112:29 pmRNSXeris Pharmaceuticals, Inc 8.3
20th Sep 202112:14 pmGNWInvesco ltd: Form 8.3 - Xeris Pharmaceutical Inc.
17th Sep 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc.
17th Sep 20212:51 pmRNSXeris Pharmaceuticals, Inc 8.3
17th Sep 20212:05 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc
17th Sep 20211:13 pmEQSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc.
16th Sep 20213:20 pmRNSForm 8.3 - Xeris Pharmaceuticals, Inc.
16th Sep 20212:46 pmRNSXeris Pharmaceuticals, Inc 8.3
16th Sep 20211:58 pmGNWInvesco Ltd: Form 8.3 - Xeris Pharmaceutical Inc
16th Sep 202110:52 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
15th Sep 20211:58 pmRNSXeris Pharmaceuticals, Inc 8.3
15th Sep 202111:15 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC
15th Sep 202111:14 amGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
14th Sep 20212:24 pmRNSXeris Pharmaceuticals, Inc 8.3
14th Sep 20211:56 pmRNSMan Group PLC : Form 8.3 - Strongbridge biopharma plc
14th Sep 20211:03 pmRNSForm 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc.
13th Sep 202112:22 pmRNSXeris Pharmaceuticals, Inc 8.3
13th Sep 202112:15 pmGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
10th Sep 20212:42 pmRNSXeris Pharmaceuticals, Inc 8.3
10th Sep 20217:21 amGNWMan Group PLC : Form 8.3 - Strongbridge Biopharma plc
9th Sep 20211:49 pmRNSXeris Pharmaceuticals, Inc 8.3
9th Sep 202111:15 amRNSForm 8.3 - Xeris Pharmaceuticals, Inc
9th Sep 202111:13 amRNSForm 8.3 - XERIS PHARMACEUTICALS INC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.